Evidence map›Paper›PMID 41646829›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Functional Profiling of DNA Repair Pathways in Lung Cancer Patients Uncovers Radiotherapy-Induced and Cancer-Associated Alterations in Oxidative Lesion Repair.

Sneh M Toprani, Ting Zhai, Maeve Dillon-Martin, Patrick F Doyle, Claire Novack, David Kozono, Zachary D Nagel

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sneh M TopraniJohn B Little Center of Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-2388-5425
Ting ZhaiJohn B Little Center of Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Maeve Dillon-MartinDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Patrick F DoyleDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Claire NovackDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
David KozonoDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, MA, USA.
Zachary D NagelJohn B Little Center of Radiation Sciences, Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Shared Resource Core 2: Clinical Artificial Intelligence CoreU54CA274516 · NCI · DANA-FARBER CANCER INST · PI Benjamin Harris Kann · 2023 to 2026
$8.1M
Multi-Pathway DNA Repair Capacity Measurements in Lung Cancer Patients and Healthy ControlsU01ES029520 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI CHRISTIANI, DAVID C, ENGELWARD, BEVIN P. · 2018 to 2022
$3.3M
Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patientsR37CA248565 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Kristopher Andrew Sarosiek · 2020 to 2026
$2.6M
NCI NIH HHS R37 CA248565NCI NIH HHS U10 CA180821NCI NIH HHS U54 CA274516NIEHS NIH HHS U01 ES029520
6 · The paper itself

Abstract

DNA repair capacity (DRC), particularly at the pathway level, varies among individuals. While previous studies explored DRC in relation to environmental exposures and cancer risk, few measured DRC in patient-focused cohorts and were focused on one or two repair pathways only. We comprehensively profiled DRC for all the major repair pathways and DNA lesions in 100 lung cancer patients undergoing radiotherapy (RT) using advanced Fluorescence Multiplex based Host Cell Reactivation assays in blood cells before and after RT and investigated how DRC responded to RT and was influenced by clinical variables. Variation between individuals was significant in all pathways and smaller than variation within-person. DNA glycosylase activity decreased immediately following RT and subsequently returned to baseline in patients receiving high-intensity RT during the follow-up months. Lower DRC against oxidative lesions was found in cancer patients compared to healthy controls. These results highlight oxidative DNA damage repair as a sensitive marker of RT response and cancer burden upon profiling the DNA repair landscape.

Indexed as

blood biomarkersDNA repairlung cancerradiation therapy

Identifiers

PMID41646829
PMCPMC12870641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.